去乙酰化酶Sirtuins家族与非酒精性脂肪性肝病的关系

宗也凯; 刘江凯

doi:10.3969/j.issn.1001-5256.2022.10.030

去乙酰化酶Sirtuins家族与非酒精性脂肪性肝病的关系

DOI: 10.3969/j.issn.1001-5256.2022.10.030

宗也凯¹,
刘江凯^2, , ,

1.
河南中医药大学第一临床医学院，郑州 450008
2.
河南中医药大学第一附属医院脾胃肝胆科，郑州 450008

基金项目:

国家自然科学基金 (U1504825);

河南省中医管理局科研专项 (2021JDZY003);

河南省中医药拔尖人才项目 (2021-15)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：宗也凯负责论文设计，收集数据，资料分析，撰写论文并最后定稿; 刘江凯参与论文指导。

详细信息

通信作者:
刘江凯，13592553982@126.com

计量
- 文章访问数: 326
- HTML全文浏览量: 106
- PDF下载量: 46
- 被引次数: 0
出版历程
- 收稿日期: 2022-03-03
- 录用日期: 2022-04-05
- 出版日期: 2022-10-20

Association between the sirtuin family of deacetylases and nonalcoholic fatty liver disease

Yekai ZONG¹,
Jiangkai LIU^{2
, ,
,}

1.
The First Clinical Medical College of Henan University of Chinese Medicine, Zhengzhou 450008, China
2.
Department of Hepatology and Spleen-Stomach, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450008, China

Research funding:

National Natural Science Foundation of China (U1504825);

Scientific Research Special Project of Henan Administration of TCM (2021JDZY003);

Henan TCM Top-Notch Talent Program (2021-15)

More Information

Corresponding author: LIU Jiangkai, 13592553982@126.com(ORCID: 0000-0002-1529-5089)

摘要

摘要: 去乙酰化酶Sirtuins家族广泛存在于人体细胞当中，通过作用于线粒体、内质网和细胞核调节多种蛋白的翻译后化学修饰，对生物代谢过程产生影响，其参与非酒精性脂肪性肝病中的多种病理生理反应。本文对去乙酰化酶Sirtuins家族与非酒精性脂肪性肝病关系的研究进展进行了综述，旨在为今后治疗非酒精性脂肪性肝病提供可能的潜在途径。
- 非酒精性脂肪性肝病 /
- 抗衰老酶 /
- 去乙酰化
Abstract: The sirtuin family of deacetylases widely exists in human cells and can regulate the post-translational chemical modification of various proteins by acting on mitochondria, endoplasmic reticulum and nucleus, thereby influencing the process of biological metabolism. The sirtuin family is also involved in a variety of pathophysiological reactions in nonalcoholic fatty liver disease (NAFLD). This article reviews the research advances in the association between the sirtuin family of deacetylases and nonalcoholic fatty liver disease, so as to provide a potential approach for NAFLD treatment in the future.
- Non-alcoholic Fatty Liver Disease /
- Sirtuins /
- Deacetylation

HTML全文

表 1 哺乳动物Sirtuins一般特征^[8-10]

Table 1. General characteristics of Sirtuins in mammals

分型	位置	长度	催化活性	与NAFLD相关功能
SIRT1	细胞核	747 aa	脱乙酰基酶	染色质的形成，线粒体生物发生，脂肪酸氧化，胆固醇和胆汁酸稳态的调节
SIRT2	细胞质	352 aa	脱乙酰基酶脱嘧啶酶	细胞周期调节，促进脂肪细胞的脂肪分解，肿瘤抑制/促进
SIRT3	线粒体	399 aa	脱乙酰基酶	线粒体活性的调节，抗氧化应激活动，肿瘤抑制
SIRT4	线粒体	314 aa	脱乙酰基酶腺苷二磷酸核糖基转移酶脂肪酰胺酶	葡萄糖代谢，氨基酸分解代谢，肿瘤抑制
SIRT5	线粒体	310 aa	脱乙酰基酶去琥珀酸酶去谷氨酰胺酶	脂肪酸代谢，氨基酸代谢，尿素循环
SIRT6	细胞核	355 aa	脱乙酰基酶脱醛酶腺苷二磷酸核糖基转移酶脱嘧啶酶	基因组稳定性/DNA修复，糖脂代谢，发炎
SIRT7	细胞核	400 aa	脱乙酰基酶腺苷二磷酸核糖基转移酶	核糖体生物发生，肿瘤促进
注：aa，氨基酸。数据库来源：Uniprot，Genecards。

下载: 导出CSV

参考文献(52)

[1]	LAZARUS JV, MARK HE, ANSTEE QM, et al. Advancing the global public health agenda for NAFLD: a consensus statement[J]. Nat Rev Gastroenterol Hepatol, 2022, 19(1): 60-78. DOI: 10.1038/s41575-021-00523-4.
[2]	YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1): 73-84. DOI: 10.1002/hep.28431.
[3]	ZHOU F, ZHOU J, WANG W, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: A systematic review and meta-analysis[J]. Hepatology, 2019, 70(4): 1119-1133. DOI: 10.1002/hep.30702.
[4]	SHAPIRO WL, NOON SL, SCHWIMMER JB. Recent advances in the epidemiology of nonalcoholic fatty liver disease in children[J]. Pediatr Obes, 2021, 16(11): e12849. DOI: 10.1111/ijpo.12849.
[5]	WANG CE, XU WT, GONG J, et al. Research progress in treatment of nonalcoholic fatty liver disease[J]. Chin J Med Offic, 2022, 50(9): 897-899, 903. DOI: 10.16680/j.1671-3826.2022.09.06. 王彩娥, 许文涛, 宫建, 等. 非酒精性脂肪性肝病治疗研究进展[J]. 临床军医杂志, 2022, 50(9): 897-899, 903. DOI: 10.16680/j.1671-3826.2022.09.06.
[6]	FINKEL T, DENG CX, MOSTOSLAVSKY R. Recent progress in the biology and physiology of sirtuins[J]. Nature, 2009, 460(7255): 587-591. DOI: 10.1038/nature08197.
[7]	HIRSCHEY MD, ZHAO Y. Metabolic regulation by lysine malonylation, succinylation, and glutarylation[J]. Mol Cell Proteomics, 2015, 14(9): 2308-2315. DOI: 10.1074/mcp.R114.046664.
[8]	KUPIS W, PAŁYGA J, TOMAL E, et al. The role of sirtuins in cellular homeostasis[J]. J Physiol Biochem, 2016, 72(3): 371-380. DOI: 10.1007/s13105-016-0492-6.
[9]	CARAFA V, ROTILI D, FORGIONE M, et al. Sirtuin functions and modulation: from chemistry to the clinic[J]. Clin Epigenetics, 2016, 8: 61. DOI: 10.1186/s13148-016-0224-3.
[10]	SANTOS L, ESCANDE C, DENICOLA A. Potential modulation of sirtuins by oxidative stress[J]. Oxid Med Cell Longev, 2016, 2016: 9831825. DOI: 10.1155/2016/9831825.
[11]	AVILKINA V, CHAUVEAU C, GHALI MHENNI O. Sirtuin function and metabolism: Role in pancreas, liver, and adipose tissue and their crosstalk impacting bone homeostasis[J]. Bone, 2022, 154: 116232. DOI: 10.1016/j.bone.2021.116232.
[12]	BUZZETTI E, PINZANI M, TSOCHATZIS EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)[J]. Metabolism, 2016, 65(8): 1038-1048. DOI: 10.1016/j.metabol.2015.12.012.
[13]	SCORLETTI E, CARR RM. A new perspective on NAFLD: Focusing on lipid droplets[J]. J Hepatol, 2022, 76(4): 934-945. DOI: 10.1016/j.jhep.2021.11.009.
[14]	ALVES-BEZERRA M, COHEN DE. Triglyceride metabolism in the liver[J]. Compr Physiol, 2017, 8(1): 1-8. DOI: 10.1002/cphy.c170012.
[15]	PURUSHOTHAM A, SCHUG TT, XU Q, et al. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation[J]. Cell Metab, 2009, 9(4): 327-338. DOI: 10.1016/j.cmet.2009.02.006.
[16]	GOETZMAN ES, BHARATHI SS, ZHANG Y, et al. Impaired mitochondrial medium-chain fatty acid oxidation drives periportal macrovesicular steatosis in sirtuin-5 knockout mice[J]. Sci Rep, 2020, 10(1): 18367. DOI: 10.1038/s41598-020-75615-3.
[17]	LI SW, TAKAHARA T, QUE W, et al. Hydrogen-rich water protects against liver injury in nonalcoholic steatohepatitis through HO-1 enhancement via IL-10 and Sirt 1 signaling[J]. Am J Physiol Gastrointest Liver Physiol, 2021, 320(4): G450-G463. DOI: 10.1152/ajpgi.00158.2020.
[18]	FORTE TM, RYAN RO. Apolipoprotein A5: Extracellular and intracellular roles in triglyceride metabolism[J]. Curr Drug Targets, 2015, 16(12): 1274-1280. DOI: 10.2174/1389450116666150531161138.
[19]	XING D, WANG B, LU H, et al. Sirtuin 3 restores synthesis and secretion of very low-density lipoproteins in cow hepatocytes challenged with nonesterified fatty acids in vitro[J]. Vet Sci, 2021, 8(7): 121. DOI: 10.3390/vetsci8070121.
[20]	ZHU C, HUANG M, KIM HG, et al. SIRT6 controls hepatic lipogenesis by suppressing LXR, ChREBP, and SREBP1[J]. Biochim Biophys Acta Mol Basis Dis, 2021, 1867(12): 166249. DOI: 10.1016/j.bbadis.2021.166249.
[21]	SATHYANARAYAN A, MASHEK MT, MASHEK DG. ATGL promotes autophagy/lipophagy via SIRT1 to control hepatic lipid droplet catabolism[J]. Cell Rep, 2017, 19(1): 1-9. DOI: 10.1016/j.celrep.2017.03.026.
[22]	DONG Z, XIE X, SUN Y, et al. Paeonol prevents lipid metabolism dysfunction in palmitic acid-induced HepG2 injury through promoting SIRT1-FoxO1-ATG14-dependent autophagy[J]. Eur J Pharmacol, 2020, 880: 173145. DOI: 10.1016/j.ejphar.2020.173145.
[23]	ZHANG T, LIU J, SHEN S, et al. SIRT3 promotes lipophagy and chaperon-mediated autophagy to protect hepatocytes against lipotoxicity[J]. Cell Death Differ, 2020, 27(1): 329-344. DOI: 10.1038/s41418-019-0356-z.
[24]	PETERSEN MC, SHULMAN GI. Mechanisms of insulin action and insulin resistance[J]. Physiol Rev, 2018, 98(4): 2133-2223. DOI: 10.1152/physrev.00063.2017.
[25]	YARIBEYGI H, FARROKHI FR, BUTLER AE, et al. Insulin resistance: Review of the underlying molecular mechanisms[J]. J Cell Physiol, 2019, 234(6): 8152-8161. DOI: 10.1002/jcp.27603.
[26]	WANG A, LI T, AN P, et al. Exendin-4 upregulates adiponectin level in adipocytes via Sirt1/Foxo-1 signaling pathway[J]. PLoS One, 2017, 12(1): e0169469. DOI: 10.1371/journal.pone.0169469.
[27]	JUNG TW, LEE KT, LEE MW, et al. SIRT1 attenuates palmitate-induced endoplasmic reticulum stress and insulin resistance in HepG2 cells via induction of oxygen-regulated protein 150[J]. Biochem Biophys Res Commun, 2012, 422(2): 229-232. DOI: 10.1016/j.bbrc.2012.04.129.
[28]	CAO Y, JIANG X, MA H, et al. SIRT1 and insulin resistance[J]. J Diabetes Complications, 2016, 30(1): 178-183. DOI: 10.1016/j.jdiacomp.2015.08.022.
[29]	WU SY, LIANG J, YANG BC, et al. SIRT1 activation promotes β-Cell regeneration by activating endocrine progenitor cells via AMPK signaling-mediated fatty acid oxidation[J]. Stem Cells, 2019, 37(11): 1416-1428. DOI: 10.1002/stem.3073.
[30]	ZHANG HH, MA XJ, WU LN, et al. Sirtuin-3 (SIRT3) protects pancreatic β-cells from endoplasmic reticulum (ER) stress-induced apoptosis and dysfunction[J]. Mol Cell Biochem, 2016, 420(1-2): 95-106. DOI: 10.1007/s11010-016-2771-5.
[31]	LETO D, SALTIEL AR. Regulation of glucose transport by insulin: traffic control of GLUT4[J]. Nat Rev Mol Cell Biol, 2012, 13(6): 383-396. DOI: 10.1038/nrm3351.
[32]	JEON JY, CHOI SE, HA ES, et al. GLP-1 improves palmitate-induced insulin resistance in human skeletal muscle via SIRT1 activity[J]. Int J Mol Med, 2019, 44(3): 1161-1171. DOI: 10.3892/ijmm.2019.4272.
[33]	MUSSO G, GAMBINO R, CASSADER M. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis[J]. Prog Lipid Res, 2013, 52(1): 175-191. DOI: 10.1016/j.plipres.2012.11.002.
[34]	BRESQUE M, CAL K, PÉREZ-TORRADO V, et al. SIRT6 stabilization and cytoplasmic localization in macrophages regulates acute and chronic inflammation in mice[J]. J Biol Chem, 2022, 298(3): 101711. DOI: 10.1016/j.jbc.2022.101711.
[35]	KA SO, BANG IH, BAE EJ, et al. Hepatocyte-specific sirtuin 6 deletion predisposes to nonalcoholic steatohepatitis by up-regulation of Bach1, an Nrf2 repressor[J]. FASEB J, 2017, 31(9): 3999-4010. DOI: 10.1096/fj.201700098RR.
[36]	YANG XD, CHEN Z, YE L, et al. Esculin protects against methionine choline-deficient diet-induced non-alcoholic steatohepatitis by regulating the Sirt1/NF-κB p65 pathway[J]. Pharm Biol, 2021, 59(1): 922-932. DOI: 10.1080/13880209.2021.1945112.
[37]	XIAO C, WANG RH, LAHUSEN TJ, et al. Progression of chronic liver inflammation and fibrosis driven by activation of c-JUN signaling in Sirt6 mutant mice[J]. J Biol Chem, 2012, 287(50): 41903-41913. DOI: 10.1074/jbc.M112.415182.
[38]	VACHHARAJANI VT, LIU T, WANG X, et al. Sirtuins link inflammation and metabolism[J]. J Immunol Res, 2016, 2016: 8167273. DOI: 10.1155/2016/8167273.
[39]	TSUCHIDA T, FRIEDMAN SL. Mechanisms of hepatic stellate cell activation[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(7): 397-411. DOI: 10.1038/nrgastro.2017.38.
[40]	LI M, HONG W, HAO C, et al. SIRT1 antagonizes liver fibrosis by blocking hepatic stellate cell activation in mice[J]. FASEB J, 2018, 32(1): 500-511. DOI: 10.1096/fj.201700612R.
[41]	PAROLA M, PINZANI M. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues[J]. Mol Aspects Med, 2019, 65: 37-55. DOI: 10.1016/j.mam.2018.09.002.
[42]	KUNDU A, DEY P, PARK JH, et al. EX-527 prevents the progression of high-fat diet-induced hepatic steatosis and fibrosis by upregulating SIRT4 in Zucker rats[J]. Cells, 2020, 9(5): 1101. DOI: 10.3390/cells9051101.
[43]	ARTEAGA M, SHANG N, DING X, et al. Inhibition of SIRT2 suppresses hepatic fibrosis[J]. Am J Physiol Gastrointest Liver Physiol, 2016, 310(11): G1155-G1168. DOI: 10.1152/ajpgi.00271.2015.
[44]	ZHONG X, HUANG M, KIM HG, et al. SIRT6 protects against liver fibrosis by deacetylation and suppression of SMAD3 in hepatic stellate cells[J]. Cell Mol Gastroenterol Hepatol, 2020, 10(2): 341-364. DOI: 10.1016/j.jcmgh.2020.04.005.
[45]	RYU D, JO YS, LO SASSO G, et al. A SIRT7-dependent acetylation switch of GABPβ1 controls mitochondrial function[J]. Cell Metab, 2014, 20(5): 856-869. DOI: 10.1016/j.cmet.2014.08.001.
[46]	MARTÉNEZ-JIMÉNEZ V, CORTEZ-ESPINOSA N, RODRÍGUEZ-VARELA E, et al. Altered levels of sirtuin genes (SIRT1, SIRT2, SIRT3 and SIRT6) and their target genes in adipose tissue from individual with obesity[J]. Diabetes Metab Syndr, 2019, 13(1): 582-589. DOI: 10.1016/j.dsx.2018.11.011.
[47]	KIM HS, XIAO C, WANG RH, et al. Hepatic-specific disruption of SIRT6 in mice results in fatty liver formation due to enhanced glycolysis and triglyceride synthesis[J]. Cell Metab, 2010, 12(3): 224-236. DOI: 10.1016/j.cmet.2010.06.009.
[48]	SHARMA G, PARIHAR A, PARIHAR P, et al. Downregulation of sirtuin 3 by palmitic acid increases the oxidative stress, impairment of mitochondrial function, and apoptosis in liver cells[J]. J Biochem Mol Toxicol, 2019, 33(8): e22337. DOI: 10.1002/jbt.22337.
[49]	LI M, HONG W, HAO C, et al. Hepatic stellate cell-specific deletion of SIRT1 exacerbates liver fibrosis in mice[J]. Biochim Biophys Acta Mol Basis Dis, 2017, 1863(12): 3202-3211. DOI: 10.1016/j.bbadis.2017.09.008.
[50]	ZHANG J, LI Y, LIU Q, et al. Sirt6 alleviated liver fibrosis by deacetylating conserved lysine 54 on smad2 in hepatic stellate cells[J]. Hepatology, 2021, 73(3): 1140-1157. DOI: 10.1002/hep.31418.
[51]	CLAVERIA-CABELLO A, COLYN L, ARECHEDERRA M, et al. Epigenetics in liver fibrosis: Could HDACs be a therapeutic target?[J]. Cells, 2020, 9(10): 2321. DOI: 10.3390/cells9102321.
[52]	NASSIR F, IBDAH JA. Sirtuins and nonalcoholic fatty liver disease[J]. World J Gastroenterol, 2016, 22(46): 10084-10092. DOI: 10.3748/wjg.v22.i46.10084.